COVID-19: AstraZeneca supplies corona vaccine to Japan: Daiichi Sankyo, Meiji Seika Pharma
COVID-19:
British pharmaceutical giant: AstraZeneca
AstraZeneca is developing a new coronavirus vaccine with Oxford University in the UK.
On June 26, it announced that it has agreed to proceed with discussions with the Japanese government to supply the new coronavirus vaccine to Japan.
We will establish a production system for Japan in cooperation with Daiichi Sankyo and Meiji Holdings (HD) group companies.
Supply to Japan:
AstraZeneca and others are proceeding with clinical trials of the new corona vaccine.
For supply to Japan, AstraZeneca will provide the stock solution of the vaccine.
Daiichi Sankyo Group:
Daiichi Sankyo Group/Daiichi Sankyo Biotech (Kitamoto City, Saitama Prefecture) and Meiji HD/KM Biologics (Kumamoto City) will be involved.
Meiji HD:
We will also utilize the vaccine distribution and supply scheme of Meiji Seika Pharma (Tokyo, Central), which is under the umbrella of Meiji HD.
Nihon Keizai Shimbun
https://r.nikkei.com/article/DGXMZO60835900W0A620C2MM8000?s=4
New Corona: Chief Cabinet Secretary “Agreement is Fact”
https://r.nikkei.com/article/DGXMZO60839710W0A620C2000000?n_cid=DSREA001&s=4
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
AstraZeneca
has picked up manufacturing partners at a rapid clip with a goal to produce 2 billion doses per year of the University of Oxford’s COVID-19 vaccine candidate.
And it may be close to adding to that partner list: The British drugmaker and Daiichi Sankyo are in talks to knock together a supply deal for Japan.
AstraZeneca and Daiichi Sankyo
are chipping away at a Japanese supply deal for Oxford’s adenovirus-based COVID-19 vaccine, AZD1222, that would include fill-finish and storage duties, Daiichi said Friday.
The supply talks
come after AstraZeneca and the Japanese government agreed to sit down at the negotiating table to discuss a possible deal, Daiichi said.
Daiichi Sankyo Biotech,
a subsidiary of the Japanese drugmaker,
plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities.
FiercePharma